Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.51 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.48 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.48 |
| ▸ | CPA1 | P15085 | 1/20 | 0.46 |
| ▸ | LAP3 | P28838 | 2/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.41 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | MME | P08473 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.37 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL489084 | 1.00 | CPB2 (0.51) | CPB2SLC1A3SLC1A2CPA1LAP3 | |
| SCHEMBL6351551 | 0.84 | CPB2 (0.60) | CPB2SLC1A3SLC1A2MMEACE | |
| Hydrochloric Acid SCHEMBL10549891 | 0.82 | CPB2 (0.58) | CPB2SLC1A3SLC1A2MMEACE | |
| SCHEMBL1708851 | 0.82 | CPB2 (0.42) | CPB2SLC1A3SLC1A2CPA1LAP3 | |
| SCHEMBL9068636 | 0.82 | CPB2 (0.39) | CPB2SLC1A3SLC1A2CPA1RNPEP | |
| SCHEMBL9068534 | 0.81 | ACE (0.43) | CPB2CPA1MMEALDH1A1ACE | |
| SCHEMBL10920363 | 0.81 | ACE (0.43) | CPB2CPA1MMEALDH1A1ACE | |
| SCHEMBL9067765 | 0.79 | ALDH1A1 (0.54) | MMEALDH1A1 | |
| SCHEMBL6469867 | 0.78 | CPB2 (0.55) | CPB2SLC1A3SLC1A2MMEACE | |
| SCHEMBL11438523 | 0.78 | CPB2 (0.55) | CPB2SLC1A3SLC1A2MMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 247 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9273008-B2 | Dual-acting imidazole antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273008-B2 | Dual-acting imidazole antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273008-B2 | Dual-acting imidazole antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-03-01 | — | — | US | disclosed |
| US-9198899-B2 | Dual-acting benzoimidazole antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-12-01 | — | — | US | disclosed |
| US-9198899-B2 | Dual-acting benzoimidazole antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-12-01 | — | — | US | disclosed |
| US-9198899-B2 | Dual-acting benzoimidazole antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-12-01 | — | — | US | disclosed |
| US-9150514-B2 | Dual-acting antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-10-06 | — | — | US | disclosed |
| US-9150514-B2 | Dual-acting antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-10-06 | — | — | US | disclosed |
| US-9150514-B2 | Dual-acting antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-10-06 | — | — | US | disclosed |
| US-20150191435-A1 | DUAL-ACTING IMIDAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-07-09 | — | — | US | disclosed |
| EP-0067429-B1 | INHIBITORS OF MAMMALIAN COLLAGENASE | E.R. Squibb & Sons, Inc. (US) | 1986-04-16 | — | — | EP | disclosed |
| US-4424354-A | MERCAPTOALKANOYL DERIVATIVES OF PEPTIDES | E. R. SQUIBB & SONS, INC. (US) | 1984-01-03 | — | — | US | disclosed |
| US-4382081-A | ANTIARRTHRITIC AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1983-05-03 | — | — | US | disclosed |
| EP-0021766-B1 | INHIBITORS OF MAMMALIAN COLLAGENASE | E.R. Squibb & Sons, Inc. (US) | 1983-02-09 | — | — | EP | disclosed |
| EP-0067429-A1 | Inhibitors of mammalian collagenase | E.R. Squibb & Sons, Inc. (US) | 1982-12-22 | — | — | EP | disclosed |
| US-4327111-A | N-Substituted mercaptoacyl pripionamides | E. R. SQUIBB & SONS, INC. (US) | 1982-04-27 | — | — | US | disclosed |
| US-4297275-A | Inhibitors of mammalian collagenase | E. R. SQUIBB & SONS, INC. (US) | 1981-10-27 | — | — | US | disclosed |
| US-4263293-A | ANTIARTHRITIC AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1981-04-21 | — | — | US | disclosed |
| EP-0021766-A2 | Inhibitors of mammalian collagenase | E.R. Squibb & Sons, Inc. (US) | 1981-01-07 | — | — | EP | disclosed |
| US-4235885-A | Inhibitors of mammalian collagenase | E. R. SQUIBB & SONS, INC. (US) | 1980-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191435-A1 | DUAL-ACTING IMIDAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | CPB2 1957/4885SLC1A3 2173/4885SLC1A2 2436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.